The FDA has accepted Belite Bio’s application for tinlarebant and [...]

ATSN-401, Atsena Therapeutics’ investigational gene therapy for Stargardt disease, has [...]

AAVantgarde Bio has completed enrollment in LUCE-1, a first-in-human Phase [...]

AAVantgarde’s AAVB-039 gene therapy, targeting the root cause of Stargardt [...]

Nanoscope Therapeutics has initiated a rolling submission for its Biologics [...]